Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany

Epidemiology and Infection

Volumn 135, Issue 4, 2007, Pages 563-569

  Enders, M ^a   Weidner, A ^a   Enders, G ^a  

^a Institut fur Virologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIBODY;

ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL LABORATORY; EPIDEMIOLOGICAL DATA; EXPOSURE; GERMANY; HUMAN; INFECTION RISK; PARVOVIRUS INFECTION; PREDICTION; PREGNANCY; RASH; SEROPREVALENCE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; RISK FACTORS;

EID: 34247480037     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S095026880600731X     Document Type: Article

References (28)

1. Anderson MJ, et al. Human parvovirus, the cause of e rythema infectiosum (fifth disease)? Lancet 1983; 1: 1378.
2. Gillespie SM, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. Journal of the American Medical Association 1990; 263: 2061-2065.
3. Gratacós E, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. Journal of Infectious Diseases 1995; 171: 1360-1363.
4. Harger JH, et al. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: Risks and symptoms. Obstetrics and Gynecology 1998; 91: 413-420.
5. Maksheed M, et al. The prevalence of antibody to human parvovirus B19 in pregnant women in Kuwait. Acta Tropica 1999; 73: 225-229.
6. Enders M, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: Prospective evaluation of 1018 cases. Prenatal Diagnosis 2004; 24: 513-518.
7. Brown T, et al. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984; 2: 1033-1034.
8. PHLS. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. British Medical Journal 1990; 300: 1166-1170.
9. Miller E, et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. British Journal of Obstetrics and Gynaecology 1998; 105: 174-178.
10. Yaegashi N. Pathogenesis of nonimmune hydrops fetalis caused by intrauterine B19 infection. Tohoku Journal of Experimental Medicine 2000; 190: 65-82.
11. Searle K, Guilliard C, Enders G. Parvovirus B19 diagnosis in pregnant women - quantification of IgG anti-body levels (IU/ml) with reference to the international parvovirus B19 standard serum. Infection 1997; 25: 32-34.
12. Enders G, Biber M. Parvovirus B19 infections in pregnancy. Behring Institute Mitteilungen 1990; 85: 74-78.
13. Wiersbitzky S, et al. Seroprevalence of human parvovirus B 19 antibodies (Sticker's disease/erythema infectiosum) in the DRG population [in German]. Kinderärztliche Praxis 1990; 58: 185-189.
14. Jensen IP, et al. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: A study of socio-demographic and medical risk factors. British Journal of Obstetrics and Gynaecology 2000; 107: 637-643.
15. Knowles SJ, et al. Susceptibility to infectious rash illness in pregnant women from diverse geographical regions. Communicable Disease and Public Health 2004; 7: 344-348.
16. van Gessel PH, et al. Incidence of parvovirus B19 infection among an unselected population of pregnant women in the Netherlands: A prospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology (in press).
17. Kelly HA, et al. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiology and Infection 2000; 124: 449-457.
18. Gilbert NL, et al. Seroprevalence of parvovirus B19 infection in daycare educators. Epidemiology and Infection 2005; 133: 299-304.
19. Bremner JA, Cohen BJ. Parvovirus B19 as a cause of anemia in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 1994; 169: 938-940.
20. Crowcroft NS, Cohen BJ, Miller E. Human parvovirus B19 infection in pregnancy. Perinatology 1999; 1: 61-72.
21. Bosman A, Wallinga J, Kroes AMC. Fifth disease every four years: Parvovirus B19. Infectieziekten Bulletin 2002; 13: 215-219.
22. Morgan-Capner P, Crowcroft NS. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Communicable Disease and Public Health 2002; 5: 59-71.
23. Crane J. Parvovirus B19 infection in pregnancy. Journal of Obstetrics and Gynaecology Canada 2002; 24: 727-743.
24. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. Journal of Medical Microbiology 1988; 25: 151-153.
25. Eis-Hübinger AM, et al. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zentralblatt Bakteriologie 1996; 284: 232-240.
26. Kelly HA, et al. Fifth disease in a small rural community. What are the consequences? Australian Family Physician 1999; 28: 139-144.
27. Valeur-Jensen AK, et al. Risk factors for parvovirus B19 infection in pregnancy. Journal of the American Medical Association 1999; 281: 1099-1105.
28. CDC. Parvovirus B19 infection (Fifth Disease) (http://www.cdc.gov/ncidod/diseases/parvovirus/B19&preg.htm). Accessed 28 February 2006.